Alvotech secures $75M term loan, bringing new capital access to $240M
What's the deal? Alvotech, the Icelandic biosimilars maker, has secured a term loan facility of up to $75 million led by GoldenTree Asset ManagementDealroom has a profile for this one. Try Dealroom →.
The financing amends its existing credit agreement with GoldenTree and other lenders. It bears 12.50% interest, payable monthly in cash, and matures December 31, 2027.
Combined with a $165 million equity raise announced on June 18, 2026, the company now has access to $240 million in new capital.
Why now? Alvotech is scaling a heavy pipeline, with roughly 30 biosimilar products in development and multiple global launches underway.
Milestones ahead of the deal include resubmitting key Biologics License Applications to the US Food and Drug AdministrationDealroom has a profile for this one. Try Dealroom → and winning acceptance of its application for a biosimilar to Entyvio.
The equity offering drew more than 40 new specialist healthcare investors, signalling appetite for the next growth phase.
"Capital is the fuel that enables us to execute on that vision," said Robert WessmanDealroom has a profile for this one. Try Dealroom →, founder and chairman.
What could go wrong? The 12.50% interest rate is steep, adding pressure to a company still scaling its commercial operations.
Alvotech's growth also hinges on regulatory approvals it does not fully control, and biosimilars face crowded, price-competitive markets.
The signal: GoldenTree Asset ManagementDealroom has a profile for this one. Try Dealroom →, an investment fund and long-term financing partner to Alvotech, is deepening its commitment by adding this $75 million facility on top of the $100 million term loan it led in December 2025. For a late-stage company like Alvotech, that continued backing signals confidence in its path to profitability even as it leans on high-cost debt to fund its pipeline.
Read more: MarketScreener
Image credit: Generated with Gemini
